Awakn Life Sciences gets green light for phase III trial in SAUD treatment By Investing.com – Canada Boosts
© Reuters. Awakn Life Sciences Corp., a Toronto-based biotech agency, has obtained crucial approvals to advance its pioneering therapy for Extreme Alcohol Use Dysfunction (SAUD). The Medicines and Healthcare merchandise Regulatory Company (MHRA) and the UK Well being Analysis Authority have sanctioned a part III scientific trial for AWKN-P001, a drug combining ketamine and psycho-social…